CR20220334A - Anticuerpos específicos de apolipoproteína l1 y métodos de uso - Google Patents
Anticuerpos específicos de apolipoproteína l1 y métodos de usoInfo
- Publication number
- CR20220334A CR20220334A CR20220334A CR20220334A CR20220334A CR 20220334 A CR20220334 A CR 20220334A CR 20220334 A CR20220334 A CR 20220334A CR 20220334 A CR20220334 A CR 20220334A CR 20220334 A CR20220334 A CR 20220334A
- Authority
- CR
- Costa Rica
- Prior art keywords
- apol1
- apolipoprotein
- methods
- specific antibodies
- differentiate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
Abstract
La presente divulgación proporciona anticuerpos anti-apolipoproteína L1 (APOL1), que incluyen anticuerpos anti-APOL1 que diferencian las formas de G0 y G1 de la forma de G2 de APOL1, diferencian APOL1 encontrada en podocitos en lugar de la encontrada en partículas de HDL en suero y diferencian APOL1 de apolipoproteínas L2, L3, L4 y L6 (APOL2, APOL3, APOL4 y APOL6), y los métodos para su uso.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962953097P | 2019-12-23 | 2019-12-23 | |
PCT/US2020/066377 WO2021133723A2 (en) | 2019-12-23 | 2020-12-21 | Apolipoprotein l1-specific antibodies and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20220334A true CR20220334A (es) | 2022-08-26 |
Family
ID=74191928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20220334A CR20220334A (es) | 2019-12-23 | 2020-12-21 | Anticuerpos específicos de apolipoproteína l1 y métodos de uso |
Country Status (15)
Country | Link |
---|---|
US (1) | US20230071609A1 (es) |
EP (1) | EP4081294A2 (es) |
JP (1) | JP2023509390A (es) |
KR (1) | KR20220118527A (es) |
CN (1) | CN115515678A (es) |
AU (1) | AU2020412609A1 (es) |
BR (1) | BR112022012439A2 (es) |
CA (1) | CA3165504A1 (es) |
CL (1) | CL2022001714A1 (es) |
CO (1) | CO2022010235A2 (es) |
CR (1) | CR20220334A (es) |
IL (1) | IL294131A (es) |
MX (1) | MX2022007746A (es) |
PE (1) | PE20221186A1 (es) |
WO (1) | WO2021133723A2 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023086901A1 (en) * | 2021-11-12 | 2023-05-19 | Virginia Tech Intellectual Properties, Inc. | Borrelia burgdorferi peptidoglycan detection methods |
WO2023178208A2 (en) * | 2022-03-16 | 2023-09-21 | Stcube & Co., Inc. | Btn1a1 binding proteins and methods of use thereof |
WO2024050524A1 (en) * | 2022-09-01 | 2024-03-07 | University Of Georgia Research Foundation, Inc. | Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
KR0184860B1 (ko) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법) |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
CA2149329C (en) | 1992-11-13 | 2008-07-15 | Darrell R. Anderson | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
DE69830901T2 (de) | 1997-05-02 | 2006-05-24 | Genentech Inc., San Francisco | ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
ATE531812T1 (de) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | Humanisierung von nager-antikörpern |
CA2378403A1 (en) | 1999-07-26 | 2001-02-01 | Genentech, Inc. | Novel polynucleotides and method for the use thereof |
AU782626B2 (en) | 1999-10-04 | 2005-08-18 | Medicago Inc. | Method for regulating transcription of foreign genes |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
ES2528794T3 (es) | 2000-04-11 | 2015-02-12 | Genentech, Inc. | Anticuerpos multivalentes y usos de los mismos |
US7635472B2 (en) | 2003-05-31 | 2009-12-22 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
MXPA06011199A (es) | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
AU2006301492B2 (en) | 2005-10-11 | 2011-06-09 | Amgen Research (Munich) Gmbh | Compositions comprising cross-species-specific antibodies and uses thereof |
US20080044455A1 (en) | 2006-08-21 | 2008-02-21 | Chaim Welczer | Tonsillitus Treatment |
EP2471816A1 (en) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
LT2520590T (lt) | 2007-04-03 | 2018-09-10 | Amgen Research (Munich) Gmbh | Susijusioms rūšims specifinis rišantis domenas |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
CA2756244A1 (en) | 2009-04-02 | 2010-10-07 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
EP2417156B1 (en) | 2009-04-07 | 2015-02-11 | Roche Glycart AG | Trivalent, bispecific antibodies |
WO2010136172A1 (en) | 2009-05-27 | 2010-12-02 | F. Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
RU2015153109A (ru) | 2009-09-16 | 2019-01-15 | Дженентек, Инк. | Содержащие суперспираль и/или привязку белковые комплексы и их применения |
CN103748114B (zh) | 2011-08-23 | 2017-07-21 | 罗切格利卡特公司 | T细胞活化性双特异性抗原结合分子 |
SI2748202T1 (sl) | 2011-08-23 | 2018-10-30 | Roche Glycart Ag | Bispecifične molekule, ki se vežejo na antigen |
KR101870555B1 (ko) | 2011-08-23 | 2018-06-22 | 로슈 글리카트 아게 | T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법 |
CN105849124B (zh) | 2013-12-20 | 2022-04-12 | 豪夫迈·罗氏有限公司 | 双重特异性抗体 |
UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
CN106573986A (zh) | 2014-07-29 | 2017-04-19 | 豪夫迈·罗氏有限公司 | 多特异性抗体 |
PE20170263A1 (es) | 2014-08-04 | 2017-03-30 | Hoffmann La Roche | Moleculas biespecificas de union a antigeno activadoras de celulas t |
EP3552488A1 (en) * | 2014-11-10 | 2019-10-16 | F. Hoffmann-La Roche AG | Animal model for nephropathy and agents for treating the same |
CN107787332B (zh) | 2015-04-24 | 2022-09-09 | 豪夫迈·罗氏有限公司 | 多特异性抗原结合蛋白 |
-
2020
- 2020-12-21 KR KR1020227025218A patent/KR20220118527A/ko unknown
- 2020-12-21 CR CR20220334A patent/CR20220334A/es unknown
- 2020-12-21 BR BR112022012439A patent/BR112022012439A2/pt unknown
- 2020-12-21 AU AU2020412609A patent/AU2020412609A1/en active Pending
- 2020-12-21 WO PCT/US2020/066377 patent/WO2021133723A2/en active Application Filing
- 2020-12-21 CN CN202080096952.1A patent/CN115515678A/zh active Pending
- 2020-12-21 IL IL294131A patent/IL294131A/en unknown
- 2020-12-21 EP EP20842842.5A patent/EP4081294A2/en active Pending
- 2020-12-21 MX MX2022007746A patent/MX2022007746A/es unknown
- 2020-12-21 PE PE2022001163A patent/PE20221186A1/es unknown
- 2020-12-21 CA CA3165504A patent/CA3165504A1/en active Pending
- 2020-12-21 JP JP2022538362A patent/JP2023509390A/ja active Pending
-
2022
- 2022-06-22 US US17/846,744 patent/US20230071609A1/en active Pending
- 2022-06-22 CL CL2022001714A patent/CL2022001714A1/es unknown
- 2022-07-19 CO CONC2022/0010235A patent/CO2022010235A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP4081294A2 (en) | 2022-11-02 |
US20230071609A1 (en) | 2023-03-09 |
CL2022001714A1 (es) | 2023-03-03 |
KR20220118527A (ko) | 2022-08-25 |
BR112022012439A2 (pt) | 2022-09-06 |
WO2021133723A3 (en) | 2021-08-05 |
CO2022010235A2 (es) | 2022-08-09 |
AU2020412609A1 (en) | 2022-06-16 |
CA3165504A1 (en) | 2021-07-01 |
WO2021133723A2 (en) | 2021-07-01 |
JP2023509390A (ja) | 2023-03-08 |
IL294131A (en) | 2022-08-01 |
CN115515678A (zh) | 2022-12-23 |
MX2022007746A (es) | 2022-10-07 |
PE20221186A1 (es) | 2022-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022001714A1 (es) | Anticuerpos específicos de apolipoproteína l1 y métodos de uso. | |
UY38403A (es) | Moduladores de la alfa-1 antitripsina | |
CL2022002771A1 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 y su uso (divisional de cl 201703195). | |
DOP2019000180A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
CL2019003114A1 (es) | Anticuerpos anti–tau y métodos de uso (divisional solicitud 201703063) | |
PE20200733A1 (es) | Inhibidores de kras g 12c y metodos para su uso | |
CL2017000902A1 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
GT199900147A (es) | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
CL2007000361A1 (es) | Combinacion que comprende un inhibidor de la arn polimerasa del virus de la hepatitis c (vhc) y un inhibidor de la proteasa del vhc; composicion farmaceutica que la comprende; y uso de la combinacion para tratar trastornos asociados con vhc. | |
CR20150088A (es) | Anticuerpos anti-notch1 nrr | |
ECSP21052184A (es) | Inhibidores de apol1 y sus métodos de uso | |
CR20180605A (es) | Anticuerpos anti-cd40 y sus usos | |
BR112017009440A2 (pt) | uso de composições que modulam a estrutura de cromatina quanto à doença do enxerto versus hospedeiro (gvhd) | |
CO2017011238A2 (es) | Anticuerpos anti-c1s humanizados | |
CR20160379A (es) | Anticuerpos biespecificos anti-il 13/il-17 y sus usos | |
CL2021000328A1 (es) | Inhibidores de transglutaminasa 2 (tg2) | |
CL2018003349A1 (es) | Combinación de anticuerpo anti-cd20, inhibidor selectivo de pelasa de p13, e inhibidor de btk para tratar trastornos proliferativos de células b. | |
UY28097A1 (es) | Activadores de ppar | |
MX2021010545A (es) | Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de la disfunción crónica del aloinjerto pulmonar. | |
CL2021000855A1 (es) | Replicones basados en alfavirus para la administración de bioterapias. | |
ECSP088743A (es) | Anticuerpos para egfl7 y métodos para su uso | |
CO2020007895A2 (es) | Inhibidores de histona acetiltransferasa de la familia myst | |
CO2023010023A2 (es) | Inhibidores de cdk2 y métodos de uso de los mismos | |
CL2022000492A1 (es) | Proceso para la preparación de estetrol de alta pureza. | |
CL2020002959A1 (es) | Tratamiento de enfermedades asociadas con el envejecimiento con moduladores de la leucotrieno a4 hidrolasa. |